42 completed, 17 terminated, 14 active not recruiting, 12 recruiting. 31 Phase 2, 15 Phase 3, 12 Phase 1, 11 Not applicable.
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OPTIMISE Lung SABR Five fraction Image-guided Stereotactic Ablative Radiotherapy (IG-SABR) treatment, Investigational three fraction image-guided Stereotactic Ablative Radiotherapy (IG-SABR) - Non Small Cell Lung Cancer | Phase 2 | Recruiting | Cancer Trials Ireland | 208 | 2026-10-01 | 2026-10-16 |
| INSPIRE: INnovative SABR for Prostate Cancer All IREland Next generation Stereotactic Ablative Radiotherapy (SABR) - Prostate Adenocarcinoma | Phase 2 | Recruiting | Cancer Trials Ireland | 136 | 2026-04-23 | 2026-07-06 |
| Precision Oncology Clinical Diagnostic Study In Primary and Metastatic Breast Cancer (PRISM) TSO500 Assay - Breast Cancer | Not applicable | Recruiting | Cancer Trials Ireland | 1600 | 2025-11-11 | 2026-02-20 |
| Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors iMAB, cMAB - Prostate Cancer | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 1600 | 2025-05-23 | 2025-09-19 |
| Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial) Control, Intervention - Pancreatic Cancer | Not applicable | Recruiting | Cancer Trials Ireland | 70 | 2024-05-01 | 2025-07-08 |
| Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas) Dose-Painted Intensity Modulated Radiotherapy - Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Cancer Trials Ireland | 49 | 2024-01-30 | 2025-07-20 |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) Elacestrant, Tamoxifen, Letrozole 2.5mg - ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 220 | 2023-12-15 | 2026-10-07 |
| Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases Radiation: image guided dose escalated SABR using a simultaneous integrated boost (SIB) - Solid Tumor Spine Metastases | Phase 1 / Phase 2 | Recruiting | Cancer Trials Ireland | 126 | 2023-11-21 | 2025-04-30 |
| Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) trastuzumab deruxtecan (T-DXd) (IV) - HER2-positive Breast Cancer | Phase 2 | Active not recruiting | Cancer Trials Ireland | 11 | 2023-10-26 | 2024-08-05 |
| PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer Trametinib, Hydroxychloroquine - Pancreatic Cancer | Phase 2 | Terminated | Cancer Trials Ireland | 20 | 2023-05-31 | 2026-04-13 |
| Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma Isatuximab, Bortezomib, Lenalidomide - Multiple Myeloma | Phase 2 | Active not recruiting | Cancer Trials Ireland | 54 | 2022-04-01 | 2025-07-08 |
| Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer Lithium, Oxaliplatin, Capecitabine - Colorectal Neoplasms, Stomach Neoplasm | Phase 1 | Terminated | Cancer Trials Ireland | 2 | 2022-01-13 | 2025-07-08 |
| CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. Daratumumab, Cyclophosphamide, Pomalidomide - Multiple Myeloma | Phase 1 | Active not recruiting | Cancer Trials Ireland | 16 | 2021-12-08 | 2026-04-13 |
| Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) Ibrutinib, Venetoclax, Obinutuzumab - Chronic Lymphoid Leukemia | Phase 3 | Active not recruiting | German CLL Study Group | 897 | 2021-03-01 | 2026-04-30 |
| 'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung) Image-Guided Stereotactic Ablative Radiotherapy (IG-SABR) - NSCLC/Oligometastatic Cancer (Single Lung Lesion) | Phase 2 | Recruiting | Cancer Trials Ireland | 68 | 2020-12-22 | 2025-05-02 |
| Sacituzumab Govitecan in Primary HER2-negative Breast Cancer Capecitabine, Carboplatin, Cisplatin - HER2-negative Breast Cancer, Triple Negative Breast Cancer | Phase 3 | Active not recruiting | GBG Forschungs GmbH | 1332 | 2020-10-28 | 2026-04-22 |
| Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer Paricalcitol, Gemcitabine (GEM) and Nab-paclitaxel - Advanced Pancreatic Cancer | Phase 2 | Completed | Cancer Trials Ireland | 15 | 2020-10-16 | 2024-03-06 |
| The COVID-IYON Study - Study Examining Data Pertaining to Clinical Outcomes and Organisational Responses to the 2020 SARS-CoV-2 Pandemic" Cancer, COVID-19 | Terminated | Cancer Trials Ireland | 4 | 2020-04-29 | 2020-10-30 | |
| Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog - Prostate Cancer | Phase 3 | Active not recruiting | University of Sydney | 1100 | 2020-03-31 | 2026-05-06 |
| Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma Wide Local Excision = 1cm Margin, Wide Local Excision = 2cm Margin - Cutaneous Melanoma, Stage II | Not applicable | Recruiting | Melanoma and Skin Cancer Trials Limited | 2998 | 2019-12-17 | 2024-11-27 |
Showing 20 of 89. Sign in to see all of them.
Breast Neoplasms (18) · Prostatic Neoplasms (13) · Carcinoma, Non-Small-Cell Lung (9) · Lung Neoplasms (7) · Neoplasm Metastasis (6) · Colorectal Neoplasms (5) · Multiple Myeloma (5) · Melanoma (4) · Neoplasms (4) · Pancreatic Neoplasms (4) · Esophageal Neoplasms (3) · Breast Neoplasms, Male (2) · Carcinoma, Ductal, Breast (2) · Colonic Neoplasms (2) · Leukemia (2)
Bortezomib (5) · Capecitabine (5) · Cisplatin (5) · Cyclophosphamide (5) · Dexamethasone (5) · Docetaxel (5) · Lapatinib (5) · enzalutamide (5) · Epirubicin (4) · Radiotherapy, Conformal (4) · Trastuzumab (4) · Carboplatin (3) · Oxaliplatin (3) · Radiotherapy (3) · Cytogenetic Analysis (2)
Ireland (86) · United Kingdom (15) · Belgium (10) · Spain (10) · Germany (9) · Canada (8) · France (8) · Netherlands (8) · Australia (7) · Denmark (7) · Sweden (7) · Switzerland (7) · United States (7) · Italy (6) · New Zealand (6)
Pierre Thirion, MD (5) · John Gerard Armstrong, MD, MB, MRCPI (4) · Ray McDermott, MD (3) · Bertrand Tombal, Prof (2) · Christopher Sweeney (2) · John Crown, MD (2) · Pierre Thirion, Dr (2) · Prof Ray McDermott (2) · Prof. Bryan Hennessy (2) · Ray McDermott, Prof (2) · Silke Gillessen, Prof (2) · Alexey Shevchuk (1) · Austin Duffy (1) · Barbara Eichhorst, MD, Prof. (1)
PMID 26392096, PMID 28399921, PMID 28578652, PMID 28750640, PMID 28925785, PMID 29525541, PMID 29528761, PMID 29548561, PMID 30157803, PMID 31157964, PMID 31201169, PMID 31384312, PMID 31576173, PMID 32157242, PMID 32203696, PMID 32370765, PMID 32601378, PMID 32713940, PMID 33208158, PMID 34090143, PMID 34928708, PMID 35132679, PMID 35876391, PMID 35934006, PMID 36482188, PMID 36648259, PMID 36990608, PMID 37163621, PMID 37172204, PMID 37507543, PMID 37650664, PMID 37734399, PMID 38233810, PMID 38416430, PMID 38620092, PMID 38821083, PMID 38852945, PMID 39353164, PMID 39404227, PMID 39453395, PMID 39693793, PMID 39827019, PMID 40468999, PMID 41313045, PMID 41358601, PMID 41535788, PMID 41911073, PMID 42837320
2014 (3), 2019 (2), 2005 (1), 2008 (1), 2015 (1)